Sanofi's LixiLan Succeeds In Second Pivotal Trial But Benefit Still Uncertain
This article was originally published in Scrip
Executive Summary
Sanofi's basal insulin/GPL-1 agonist combination LixiLan (lixisenatide plus insulin glargine) has met its primary endpoint in a second Phase III study, top-line data show, keeping it on track for filings in the US in the fourth quarter and in the EU in early 2016.